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Sepsis, insulin and noninvasive ventilation
Richard Venn
Critical Care 2002, 6:93-94
The paper reports presented here reflect the current leading
issues in the intensive care literature, the search for the ‘magic
bullet’ in sepsis being an obvious example. Many of the trials in
sepsis that are currently being reported were presented at
recent conferences [1]. This is the case for the KyperSept
Antithrombin III Study (see paper report) [2]. The summary of
this paper highlights the disappointment of the study: “ATIII
[antithrombin III] joins a long list of promising experimental
agents for sepsis that failed to show a significant benefit in a
multicentre, randomised phase III clinical trial.”
Although some success has been reported with ‘magic bullet’
studies [3], the paper by Rivers and colleagues (see paper
report) [4] puts these to shame by demonstrating a superlative
outcome benefit with essentially good early resuscitative care
in severe sepsis and septic shock. Goal-directed therapy in the
emergency department for patients with severe sepsis and
septic shock improved survival from 46.5% (control) to 30.5%
(goal-directed therapy). This was achieved by targeting central
venous saturation – an investigation that could easily be per-
formed in most modern emergency departments – and the
resultant treatment was by no means complicated or expen-
sive: increased fluids and/or blood, and occasionally dobuta-
mine for inotropic support. That study mirrors the already
impressive and abundant evidence for goal-directed therapy in
another patient population – the high-risk surgical patient [5]. It
is incredible, yet disconcerting, that a relatively basic but suc-
cessful and cheap treatment for the high risk or critically ill
patient is not current practiced in many intensive care units.
However, the expensive practice of magic bullets will no doubt
be enthusiastically received, despite the fact that the results
are far less impressive. The report of Rivers and colleagues [4]
emphasizes the enormous benefits that may be achieved by
early, good, basic critical care management.
The benefits of noninvasive ventilation once again feature
prominently in our paper reports [6]. Patients with acute hypox-
aemic respiratory failure following lung resection were random-
ized to standard care with or without nonintermittent positive
pressure ventilation. Not surprisingly, the need for extubation
was significantly higher in the control group, as was hospital
and 120-day mortality. It would be interesting to know whether
this mortality benefit remained significant if the randomization
had been to nonintermittent positive pressure ventilation versus
invasive ventilation.
Hormone therapy has always been popular in the critically ill,
and one report [7] investigated intensive insulin therapy in non-
diabetic surgical and critically ill patients. Crude hospital mor-
tality was 7.2% in the intensive therapy group versus 10.9% in
the control group (P = 0.01), and this benefit was associated
with a 46% reduction in bloodstream infections.
Finally a Canadian study [8] derived the ‘Canadian C-spine
rule’ in order to allow more selective and specific ordering of
C-spine X-rays in trauma patients who are alert and stable.
The derived rule had a sensitivity of 100% and specificity of
42.5%.
As was highlighted in the first paper report overview published
back in November 1999 [9], there has been an exponential
growth in the amount of literature specific to intensive care and
related fields. “This is set against the background of an ever-
increasing service commitment and so time is at a premium to
reflect on important breakthroughs in the literature,” it said. Our
paper reporters, who are few in number as compared with the
amount of evidence based literature out there, are not immune
to these time constraints. If you, the reader, would like more
papers critiqued, or even to join our ‘merry band of reporters’,
contact us on editorial@ccforum.com.
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C-spine rule for radiography in trauma patients
Stiell IG, Wells GA, Vandemheen KL, Clement CM, Lesiuk H,
De Maio VJ, Laupacis A, Schull M, McKnight RD, Verbeek R,
Brison R, Cass D, Dreyer J, Eisenhauer MA, Greenberg GH,
MacPhail I, Morrison L, Reardon M, Worthington J: The
Canadian C-Spine Rule for Radiography in alert and Stable
Trauma Patients. JAMA 2001, 286:1841-1848.
Topic: Audit and management, Scoring/outcome, Trauma
Reported by: Arpan Guha
Paper report publication date: 4 January 2002
Keywords: injury, cervical spine; radiological imaging; alert,
stable trauma patients
Level of evidence: Level V
Context:  The cervical spine (C-spine) of trauma victims has
been routinely imaged radiologically to rule out bony injury.
Many trauma experts find this exercise unnecessary in the major-
ity of cases who are alert, and without clinical suspicion of injury.
This study has three aims: to evaluate the possibility of being
more selective and specific in ordering C-spine X-rays in trauma
patients who are alert and stable; to examine possible predictor
variables against actual patient outcome; and to provide a ‘rule’
that will be clinically effective in decision-making.
Significant findings: A variety of data were collected from
patients with blunt trauma. These variables (e.g. mechanism of
injury, neck pain, whether radiography was performed, etc)
were then analyzed to find the best combination of predictor
variables for detecting clinically important C-spine injury with
high sensitivity and specificity. This information was used to
derive a rule, which was validated by comparing the classifica-
tion of patients to their actual status.
Radiology identified clinically significant C-spine injury in 151
(1.7%) patients. The derived rule identified these with a sensi-
tivity of 100% (95% confidence interval) and a specificity of
42.5 %(95 % CI). The authors were able to provide recom-
mendations for situations where C-spine radiography is war-
ranted so that resources are used efficiently without
jeopardising patient care. Finally, they derived the present
‘Canadian C-spine rule’.
Comments:  At present there is no well defined algorithm
based on research that would allow clinicians to minimise radi-
ological imaging of the C-spine without putting patients at risk.
This study attempts to fill that gap in our practice.
There is a potential to miss clinically unimportant (i.e. spinal
injury that requires neither stabilization, nor follow up). There
were also some patients in the study who did not undergo C-
spine radiography if the attending doctors felt that it was not
warranted (which is normal practice in Canada).
Methods: A total of 8924 adult patients with significant acute
blunt trauma to the head or neck presented to the Emergency
Departments of 10 large Canadian community and University
hospitals, these were studied as a prospective cohort.
Patients were alert and stable as defined by cardiorespiratory
parameters.
The primary outcome measure was the incidence of clinically
important C-spine injury. Patients underwent plain radiography
of the C-spine and some also had flexion–extension views and
CT of the C-spine. Patients who did not have any diagnostic
radiological imaging were followed up for 14 days.
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The golden hours of septic shock?
Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich
B, Peterson E, Tomlanovich M: Early goal directed therapy in
the treatment of severe sepsis and septic shock. N Engl J
Med 2001, 345:1368-1377.
Topic: Monitoring, Scoring/outcome, Sepsis
Paper report publication date: 19 December 2001
Reported by: Jeremy Bewley
Keywords: Sepsis, septic shock, resuscitation, treatment,
mortality, outcome
Level of evidence: Level I
Context: Goal directed haemodynamic optimisation has been
demonstrated to increase mortality when initiated on the inten-
sive care unit (ICU). This study is original as it recruits patients
particularly early, in the hospital emergency department before
admission to the ICU. Secondly it uses central venous satura-
tion as the resuscitation end point.
Significant findings: A reduced hospital mortality was found in
the treatment of severe sepsis, from 46.5% with standard treat-
ment to 30.5% with early goal directed therapy. The proposed
reason for this was a significantly higher mean central venous
saturation (77% vs 66%). This was achieved through
increased use of fluids (5 litres vs 3.5 litres), blood (64% vs
19%), and dobutamine (14% vs 1%) during the first 6 hours of
care in the emergency department.
Comments:  This is a well-designed randomised study that
addresses the important question of resuscitation of patients
with septic shock. It is not easy to blind clinicians in such a
study so bias is possible, especially as many of the patients in
the treatment arm spent longer in the emergency department
and received blood transfusions. This study demonstrates that
increased administration of fluids and more controversially
blood can reduce mortality when administered early. Dobuta-
mine was only administered to a relatively small number of
patients whilst there was no difference in the use of other vaso-
pressors. The value of central venous saturation monitoring
could be debated as a target central venous pressure (CVP) of
12–16 mmHg may have achieved the same results. Despite
this the study demonstrates that early aggressive resuscitation
is successful in reducing mortality and can be undertaken with
the use of simple resuscitation end points. Studies of longer
duration and using other centres would be valuable for confirm-
ing this benefit.
Methods: 263 patients with severe sepsis who were either in a
state of shock or had a lactate >4 mmol/l were randomised
between an initial 6 hours of either early goal directed therapy
or standard therapy. Both groups were managed with arterial
and central venous monitoring. The goal directed group had a
target central venous saturation of >70% in addition to the
standard targets of central venous pressure (CVP)
8–12 mmHg, mean arterial pressure 65–90 mmHg, and urine
output >0.5 ml/Kg/min.
Additional information: Accompanying editorial: Evans T:
Hemodynamic and Metabolic Therapy in Critically Ill
Patients. N Engl J Med 2001, 345:1417-1418.
Antithrombin III and sepsis
Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I,
Chalupa P, Atherstone A, Pénzes I, Kübler A, Knaub S,
Keinecke H-O, Heinrichs H, Schindel F, Juers M, Bone RC,
Opal SM, for the KyberSept Trial Study Group: High-dose
antithrombin III in severe sepsis: a randomised controlled
trial. JAMA 2001, 286:1869-1878.
Topic: Pharmacology, Scoring/Outcome, Sepsis
Reported by: Richard Venn
Paper report publication date: 14 November 2001
Keywords: Antithrombin III, outcome, sepsis
Level of evidence: Level 1
Context:  Uncontrolled activation of the coagulation system
may contribute to the mortality associated with septic shock.
This phase III multicentre trial investigated the role of antithrom-
bin III (ATIII), a serine protease inhibitor affecting multiple
aspects of the coagulation cascade, in patients with severe
sepsis and septic shock.
Significant findings: The baseline ATIII activity was approximately
60% in both groups. This rose to 180% in ATIII group at 24
hours; there was no change in the placebo group at 24 hours.
Overall mortality at 28 days was 38.9% in the ATIII group
versus 38.7% in the placebo group; similarly, there was no dif-
ference at 90 days.
Statistical evidence for interaction between heparin and ATIII
can be derived from multiple logistic regression analysis. There
was a significant mortality benefit at 90 days for patients not
receiving heparin: 352 (49%) in the ATIII group versus 346
(52.5%) in the placebo group (P = 0.03).
Overall there was no difference between groups except for
bleeding events, which had an incidence of 22% in the ATIII
group and 13% in the placebo group (P < 0.001); this was
most marked in patients receiving concomitant heparin
therapy.Critical Care    February 2002 Vol 6 No 1 Paper reports
Tight glucose control in the critically ill improves survival
Van den Berghe G, Wouters P, Weekers F, Verwaest C,
Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers
P, Bouillon R: Intensive insulin therapy in critically ill
patients. N Engl J Med 2001, 345:1359-1367.
Topics: Outcome
Reported by: Ognjen Gajic
Paper report publication date: 21 November 2001
Keywords: Hyperglycemia, multiple organ failure
Level of Evidence: Level I
Context: Stress induced hyperglycemia is common in critically
ill patients and may be associated with an increased rate of
infectious complications (see Additional information [1]).
Harmful effects of growth hormone therapy (see Additional
information [2]) and parenteral nutrition (see Additional informa-
tion [3]) may be related, at least in part, to the prevalence of
hyperglycemia in critically ill patients. Intensive glucose man-
agement has been shown to improve survival in patients with
diabetes mellitus and acute myocardial infarction (see Addi-
tional information [4]). This controlled trial investigates glucose
management in nondiabetic surgical and critically ill patients.
Significant findings: In total, 1548 patients were enrolled.
There were no significant differences between the intensive-
therapy group and control group at randomization.
Following intervention the mean morning glucose levels were
103 mg/dl in the intensive-therapy group versus 153 mg/dl in
the control group. Crude hospital mortality was 7.2% in the
intensive-therapy group and 10.9% in the control group
(P = 0.01). The benefit was even more significant in the sub-
group of patients receiving intensive care for >5 days (mortality
rate 16.8% versus 26.3%). The mortality benefit was associ-
ated with a 46% decrease in bloodstream infections.
Comments: Although nonblinded and restricted to patients
undergoing cardiac surgery this study will, in all likelihood, have a
great impact on the management of critically ill patients. For dia-
betic patients with acute myocardial infarction and for patients
with or without diabetes mellitus recovering from cardiac surgery,
data appear strong. There is no reason to believe this would not
be applicable to critically ill patients in general.
Methods: Patients receiving mechanical ventilation in a cardiac
surgery intensive care unit were randomized to conventional
(insulin drip only if blood glucose level above 200 mg/dl) and
strict glucose control (insulin drip to maintain normal blood
glucose level(80-110 mg/dl).
Additional Information:
1. McCowen KC, Malhotra A, Bistrian BR: Stress-induced
hyperglycemia. Crit Care Clin 2001, 17:107-124.
2. Takala J, Ruokonen E, Webster NR, Nielsen MS, Zandstra
DF, Vundelinckx G, Hinds CJ: Increased mortality associ-
ated with growth hormone treatment in critically ill
adults. N Engl J Med 1999, 341:785-792.
3. Heyland DK, MacDonald S, Keefe L, Drover JW: Total
parenteral nutrition in the critically ill patient: a meta-
analysis. JAMA 1998, 280:2013-2019.
4. Malmberg K, Norhammar A, Wedel H, Ryden: Glycometa-
bolic state at admission: important risk marker of mor-
tality in conventionally treated patients with diabetes
mellitus and acute myocardial infarction: long-term
results from the Diabetes and Insulin-Glucose Infusion
in Acute Myocardial Infarction (DIGAMI) study. Circula-
tion 1999, 99:2626-2632.
There is an editorial in the same issue: Evans TW: Hemody-
namic and metabolic therapy in critically ill patients. N Engl
J Med 2001, 345:1417-1418.
Comments: The summary to this paper highlights the disap-
pointment of this study: ATIII “joins a long list of promising
experimental agents for sepsis that failed to show a significant
benefit in a multicenter, randomised phase III clinical trial”.
Patients treated in this study with ATIII demonstrated lower
ATIII activity (180%) than was expected from preclinical trials
(200–250% activity), which may have contributed to the
absence of clinical outcome benefit. Another explanation for
this lack of benefit is that heparin competitively inhibits binding
of ATIII for glycosaminoglycans on the endothelial surface of
inflammatory cells, which would explain why those patients
without concomitant heparin therapy had an outcome advan-
tage with ATIII over placebo. Adverse bleeding events are obvi-
ously a concern in severe sepsis patients receiving ATIII.
Despite the negative result, ATIII will continue to fascinate the
intensivist, and it may be that a subgroup of severe sepsis
patients will benefit from this therapy once the optimum dosage
regime has been determined.
Methods: This was a double-blind, multicentre, phase III, ran-
domised placebo-controlled trial in which 2314 patients with
severe sepsis were randomised to receive 30,000 IU ATIII or
placebo.
Exclusions included known bleeding disorders, and heparin
therapy — except low-dose (<10,000 IU/day) subcutaneous
heparin or intravenous line flushing with heparin.http://ccforum.com/paperreport
Noninvasive ventilation after lung resection
Auriant I, Jallot A, Herve P, Cerrina J, Le Roy Ladurie F,
Fournier JL, Lescot N, Parquin F: Noninvasive ventilation
reduces mortality in acute respiratory failure following lung
resection. Am J Respir Crit Care Med 2001, 164:1231-1235.
Topics: Respiratory, Surgery, Outcome
Reported by: Ognjen Gajic
Paper report publication date: 21 November 2001
Keywords: Pneumonectomy, respiratory failure, ventilation
Level of Evidence: Level II
Context: When compared with the usual regime of oxygen sup-
plementation, noninvasive positive pressure ventilation (NIPPV)
has been shown to have a number of advantages: it can
decrease the need for endotracheal intubation in unselected
patients with acute respiratory failure (see Additional information
[1]); in immunosuppressed patients it can decrease ICU mortal-
ity (see Additional information [2]); and in a small group of
patients that had undergone lung resection it resulted in
improved gas exchange without undesirable effects (see Addi-
tional information [3]). NIPPV should not be confused with con-
tinuous positive airway pressure, which has not been shown to
be of benefit in patients with acute hypoxemic respiratory failure
(see Additional information [4]). This study compares outcomes
of either NIPPV or standard oxygen supplementation in patients
who have undergone lung resection.
Significant findings: A total of 48 patients were prospectively
enrolled (24 in each arm). The study was stopped prematurely
because of a significant difference in the primary outcome
measure, need for endotracheal intubation (20.8% versus 50%,
P = 0.035). The hospital mortality (12.5% versus 37.5%,
P = 0.045) and 120-day mortality (12.5% versus 37.5%) were
lower in the NIPPV group. There was no significant difference in
either the length of ICU (P = 0.52) or hospital (P = 0.61) stay.
Comments: This study supports the trend in current practice
towards earlier use of NIPPV in patients with acute respiratory
failure. The earlier decrease in the work of breathing and avoid-
ance of complications associated with endotracheal intubation
(e.g. infection, sedation, ventilator induced lung injury and baro-
trauma) are likely reasons for the observed decrease in mortality.
As in other NIPPV studies, patients who experienced hemody-
namic stability, excessive secretions, agitation, or extreme respi-
ratory distress were excluded from the study.
Methods:  Patients with acute hypoxemic respiratory failure
after lung resection were randomized to usual care (oxygen,
bronchodilators, chest physiotherapy) with or without NIPPV.
The study was not blinded. The primary outcome was the need
for endotracheal intubation. Secondary outcomes were hospital
and 120-day mortality, and duration of hospital and ICU stay.
Additional Information:
1. Martin TJ, Hovis JD, Costantino JP, Bierman MI, Donahoe
MP, Rogers RM, Kreit JW, Sciurba FC, Stiller RA, Sanders
MH: A randomized, prospective evaluation of noninva-
sive ventilation for acute respiratory failure. Am J Respir
Crit Care Med 2000, 161:807-813.
2. Hilbert G, Gruson D, Vargas F, Valentino R, Gbikpi-Benis-
san G, Dupon M, Reiffers J, Cardinaud JP: Noninvasive
ventilation in immunosuppressed patients with pul-
monary infiltrates, fever, and acute respiratory failure. N
Engl J Med 2001, 344:481-487.
3. Aguilo R, Togores B, Pons S, Rubi M, Barbe F, Agusti AG:
Noninvasive ventilatory support after lung resectional
surgery. Chest 1997, 112:117-121.
4. Delclaux C, L’Her E, Alberti C, Mancebo J, Abroug F, Conti
G, Guerin C, Schortgen F, Lefort Y, Antonelli M, Lepage E,
Lemaire F, Brochard L: Treatment of acute hypoxemic
nonhypercapnic respiratory insufficiency with continuous
positive airway pressure delivered by a face mask: A ran-
domized controlled trial. JAMA 2000, 284:2352-2360.
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